Back to Search
Start Over
Influence of the Glu298Asp polymorphism of NOS3 on age at onset and homocysteine levels in AD patients.
- Source :
-
Neurobiology of aging [Neurobiol Aging] 2005 Jun; Vol. 26 (6), pp. 789-94. - Publication Year :
- 2005
-
Abstract
- The distribution of the Glu298Asp polymorphism in NOS3 gene was determined in 405 Italian patients with "probable" Alzheimer's disease (AD) compared with 253 age-matched controls. Total plasma homocysteine (tHcy) levels were evaluated in 97 patients and 23 controls, and were correlated with the Glu298Asp genotype. A significantly increased frequency of the Glu/Glu genotype in late onset AD (LOAD) patients was found. tHcy levels were significantly increased in patients compared with controls and, notably, higher in LOAD than in early onset AD (EOAD). Stratifying by the Glu298Asp genotype, a trend toward an increase of tHcy was present in Glu/Glu homozygous. This wild type genotype seems to be associated with LOAD. tHcy levels are significantly increased in AD compared with controls and, moreover, higher in LOAD than in EOAD, possibly in correlation with the microvascular disease occurring with aging. Besides, a contribution of the Glu/Glu genotype in increasing tHcy levels has been observed.
- Subjects :
- Age Distribution
Age of Onset
Aged
Aged, 80 and over
Alzheimer Disease genetics
Amino Acid Substitution
Female
Genetic Predisposition to Disease genetics
Genetic Testing methods
Glutamine genetics
Humans
Italy epidemiology
Male
Middle Aged
Nitric Oxide Synthase Type III
Polymorphism, Genetic genetics
Risk Factors
Statistics as Topic
Alzheimer Disease epidemiology
Alzheimer Disease metabolism
Genetic Predisposition to Disease epidemiology
Homocysteine blood
Nitric Oxide Synthase genetics
Risk Assessment methods
Subjects
Details
- Language :
- English
- ISSN :
- 0197-4580
- Volume :
- 26
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- Neurobiology of aging
- Publication Type :
- Academic Journal
- Accession number :
- 15718036
- Full Text :
- https://doi.org/10.1016/j.neurobiolaging.2004.07.003